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ABSTRACT
HIV-1, the causative agent of AIDS, is a sophisticated
retrovirus that has both evolved to invade the complex
human immune system and adapted to utilize the host
machinery for its own propagation. A dynamic interac-
tion between the virus and host systems can be
observed at every step of the HIV-1 lifecycle. Host
factors are involved not only in mounting antiviral
responses, but are also hijacked by the virus to enhance
viral replication. Host factors are necessary for viral
replication during entry, reverse transcription, nuclear
import, integration, transcription, nuclear export,
translation, assembly, and budding. Recently, a new
class of host factors, called “host restriction factors,”
has been identified that prevent retroviral replication
in a specific host cell environment and constitute an
important part of intracellular innate immunity against
the virus. These restriction factors act as barriers to
retroviral replication at various stages within the
infected cell. Nevertheless, the HIV-1 virus has learned
to subvert these antiviral responses and successfully
propagate within the permissive host environment.
This review article describes the identification and
mechanism of action of several pro- and anti-HIV-1 host
factors. It is likely that we are only beginning to get a
glimpse of an ongoing complex battle between HIV-1
and the host, the understanding of which should
provide valuable information for the development of
novel therapeutic strategies against HIV-1. 
INTRODUCTION
Acquired Immunodeficiency Syndrome (AIDS) is a
modern day pandemic that afflicts millions of people
worldwide with a constant and bewildering increase in
the number of infected individuals. Human Immunode-
ficiency Virus type 1 (HIV-1) is a retrovirus and the
definitive causative agent of AIDS. Despite the avail-
ability of an effective and specific anti-retroviral
therapy, at the present time AIDS, is still considered an
incurable disease (Barre-Sinoussi et al., 1983; Fauci,
2003; Gallo et al., 1984; Popovic et al., 1984; Vilmer et
al., 1984). Given the devastating effects of the viral
infection on the host immune system, and the present
absence of therapy that would purge the host of the
disease, AIDS is now viewed as one of the most threat-
ening epidemics of the century (Fauci, 1999; Fauci,
2003). Therapeutic strategies designed to combat viral
replication have been successful in achieving signifi-
cant levels of reduction of the viral spread, but are not
sufficient to eliminate the virus from the host, due to
the emergence of resistant viruses and persistence of
latently-infected viral reservoirs (Belmonte et al., 2003;
Capiluppi et al., 2000; Nunnari et al., 2002; Pomerantz,
1999a; Pomerantz, 1999b; Pomerantz, 2001a; Pomer-
antz, 2001b). One of the major reasons for the emer-
gence of resistant viruses is the apparent ease with
which the low fidelity reverse transcriptase enzyme of
HIV-1 generates mutations during viral replication. The
persistence of latent viruses is due to the inability of
the current drugs to inhibit integration, a process that
mediates the insertion of reverse transcribed viral DNA
into the host genome. Thus a pressing need exists to
identify novel drug targets and new therapeutic strate-
gies to combat AIDS (Anthony, 2004; Tarrago-Litvak et
al., 2002). 
Host-virus interactions are attractive to explore for the
development of novel anti-HIV-1 strategies, as many
steps of the viral replication involve an intricate inter-
play between the virus and the host machinery (Moore
& Stevenson, 2000; Rowland-Jones et al., 2001). Given
the apparent paradox between the minimalist nature
of the retroviral genome and the complexity of the
HIV-1 lifecycle, it is essential that the virus utilizes the
host machinery both to promote its replication and, at
the same time, to subvert and evade the antiviral
responses of the cell (Freed, 2004; Ott, 2002; Popik &
Pitha, 2000; Stevenson, 2003). In recent years, it has
become apparent that virtually all the steps of viral
replication rely heavily on host cell processes. Activities
of cellular factors seem to be either hijacked by the
virus to perform the pro-viral functions, or suppressed
to minimize their potential anti-viral functions. Many
aspects of the intricate interplay between the virus and
pro-viral and anti-viral cellular proteins remain unclear,
and many participants in this process have yet to be
identified. Nevertheless, an array of cellular factors
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FIGURE 1: A Schematic Representation of the HIV-1 Lifecycle. 
The major steps in the HIV-1 replication cycle are indicated and include entry, uncoating, reverse transcription, nuclear translo-
cation of viral pre-integration complexes (PICs), integration of the viral genome into the host chromosome, transcription, RNA
export into the cytoplasm, translation, transport of viral precursor proteins to the plasma membrane, assembly, budding, matu-
ration and release. Cellular factors that promote viral replication are designated with (+) and those that inhibit viral propagation
are designated with (-).
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contributing both to propagation of the virus, and to
cellular defense has been identified in the past couple
of years, and paints a fascinating picture of the convo-
luted relationship that has evolved between the virus
and the invaded cell. Clear understanding of cellular
and viral contributors to this interplay will not only
provide insights into the mechanism of various steps of
retroviral replication, but will also likely lead to the
development of novel therapeutic strategies to specifi-
cally disrupt virus-host protein interactions (Greene &
Peterlin, 2002; Moore & Stevenson, 2000; Tang et al.,
2002). 
OVERVIEW OF HIV-1 LIFECYCLE
Viral replication takes place in several distinct steps,
and can be divided into early and late events (Freed,
2001; Freed and Martin, 2001; Goff, 2001a). Early steps
of viral replication initiate with the virus contacting the
target cell, and proceed through integration of the
viral genome into the host chromosome; late events
take place after integration and lead to the release of
newly formed virus particles from the infected cell
(Figure 1). Viral entry into the target cell is mediated by
the interaction between the envelope glycoprotein on
the mature infectious virus particle with the appro-
priate receptor (CD4) and co-receptor (CCR5 or CXCR4)
on the surface of the cell, followed by a fusion step.
Upon entry into the cell, the viral nucleoprotein
complex, sequestered within the capsid (CA) shell,
undergoes uncoating, exposing the viral machinery to
the cellular environment, and allows the initiation of
reverse transcription. The viral RNA genome is then
reverse transcribed by the virally encoded reverse tran-
scriptase (RT) to produce a linear double-stranded
cDNA molecule. The cDNA is assembled into a high
molecular weight nucleoprotein complex termed the
pre-integration complex (PIC) that contains a number
of known, as well as many unidentified, cellular and
viral proteins. The PIC is then translocated into the
nucleus of the target cell through a nuclear pore
complex (NPC). The viral cDNA carried into the nucleus
within the PIC is subsequently integrated into the host
chromosome, the process of which is catalyzed by the
virally encoded Integrase (IN). The above events consti-
tute the early stages of viral replication. During late
events the integrated viral DNA, termed the provirus, is
transcriptionally activated by the virally-encoded trans-
activator TAT and cellular transcription factors. Singly-
spliced, multiply-spliced and unspliced RNA molecules
that are formed within the nucleus are then exported
into the cytoplasm. While singly- and multiply-spliced
RNA molecules encode viral proteins, the unspliced
message is the genomic viral RNA that subsequently
gets assembled into the immature virus particle. The
assembled virus particle then buds out of the producer
cell and simultaneously undergoes maturation to form
the infectious particle. Throughout these steps of viral
replication, viral components interact with, confront
and exploit the host cellular machinery (Figure 1).
HOST FACTORS IN EARLY VIRAL REPLICATION
Receptors, Coreceptors and Lipid Rafts
One of the first observations of host factor involve-
ment in HIV-1 replication following the discovery of
HIV-1 was that the virus utilizes CD4, a member of the
immunoglobulin superfamily, as a primary receptor for
targeting the cells for infection (Dalgleish et al., 1984;
Klatzmann et al., 1984). Shortly after this discovery, it
became clear that CD4 alone was not sufficient to
support efficient HIV-1 infection, leading to the
discovery of two major coreceptors for the virus
(Alkhatib et al., 1996; Choe et al., 1996; Deng et al.,
1996; Dragic et al., 1996; Feng et al., 1996). These core-
ceptors, CCR5 and CXCR4, that belong to a family of G-
protein-coupled chemokine receptors, have been
shown to confer susceptibility to macrophage-tropic
and T cell-tropic strains of HIV-1, respectively. The core-
ceptor proteins appear to act in cooperation with CD4
to mediate efficient fusion of the virus driven by the
viral envelope (Env) proteins. CCR5 is viewed as an
attractive target for the development of antiviral
drugs, as homozygous mutation in this co-receptor in
certain individuals confers resistance to HIV-1 (Dean et
al., 1996; Liu et al., 1996; Samson et al., 1996). Selective
distribution of the co-receptors on different cell types,
which has been shown to determine the tropism of
HIV-1, has led to the classification of viruses based on
the type of co-receptors they utilize. HIV-1 that utilizes
CXCR4 is termed X4; virus utilizing CCR5 is termed R5;
and virus capable of using both types of receptors
(dual-tropic) is classified as R5X4 (Berger et al., 1999). 
Cooperative binding of viral gp120 to host CD4 and a
co-receptor promotes fusion of the virus with the cell
membrane by utilizing biological lipid membrane
microdomains called lipid rafts. Lipid rafts are rich in
cholesterol and sphingolipids and facilitate viral fusion
and entry purportedly in a pH-independent manner
(Liao et al., 2001; Liao et al., 2003; Nguyen & Taub, 2002;
Popik et al., 2002; Raulin, 2002; Viard et al., 2002). 
In addition to direct utilization of the receptor- and
coreceptor-expressing cells by HIV-1, other types of cells,
such as antigen-presenting dendritic cells (DC), appear
to be involved in HIV-1-mediated infection. The C-type
lectin, DC-SIGN, present on the surface of DC, promotes
their indirect infection by associating with the virus. DC-
SIGN binds to HIV-1 via gp120 Env and takes up and
anchors the intact virus particle, but most DC cells do not
undergo productive infection (Geijtenbeek et al., 2000;
Geijtenbeek & van Kooyk, 2003; McDonald et al., 2003).
However, HIV-1-harboring DC are believed to facilitate
viral transmission by carrying HIV-1 to its target cells. 
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Host Restriction Factors
Upon entry of the virus, CA sequesters the viral nucleo-
protein complex and encounters a multitude of host
factors within the cytoplasm of the infected cell (Goff,
2001b). Removal of the CA and release of the viral
nucleoprotein machinery into the cellular environment
constitutes the process of uncoating, which in turn
leads to the initiation of reverse transcription. For
many years it was virtually unknown how virus/host
encounters at the early post-entry stages affect subse-
quent steps of viral replication, although it was clear
that the dynamic interplay between viral factors and
cellular machinery occurring during these stages plays a
critical role in determining whether the virus would be
able to continue its propagation. Recent landmark
studies have not only shed light on the specific processes
of post-entry events, but have also imparted a deep
appreciation for the evolutionary relationship that has
developed between viruses and mammalian cells. 
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FIGURE 2: Restriction Factors Block Retroviral Infection in Mammalian Cells.
A. Friend virus susceptibility-1 (Fv1) factor, present in mouse cells, inhibits replication of murine leukemia virus (MLV). Fv1 medi-
ates its effect through the capsid protein of the incoming virus that remains associated with the viral nucleoprotein complex
throughout the early replicative events. Fv1-mediated restriction occurs after the step of reverse transcription.
B. Lentivirus susceptibility-1 factor (Lv1) and restriction factor-1 (Ref1) block replication of certain retroviruses in non-human
primates, and humans, respectively. Lv1 and Ref1 target the capsid protein of the incoming virus and block infection before the
step of reverse transcription. 
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Viruses have coexisted with cells for tens of millions of
years. The evidence of such co-existence is provided by
the endogenous retroviruses that have been incorpo-
rated into the human genome. Throughout
mammalian evolution, some viruses have progressed to
cause harm to host cells, and replication of those
viruses can result in disease (Bock & Stoye, 2000; Stoye,
2001; Sverdlov, 2000; Weiss et al., 1999). Perhaps
because of this reason, mammalian cells have devel-
oped a variety of mechanisms to protect themselves
from pathogenic viruses. Both innate immune
responses, as well as numerous adaptive immune
responses, have evolved to prevent enslaving of the
organism by viruses. In addition to global protective
mechanisms provided by the immune system, an array
of cell-autonomous factors that bestow protection
against specific viruses has evolved in mammalian cells. 
In recent years it has become apparent that these
factors act in a dominant manner to inhibit viral repli-
cation in certain cell types and play a critical role in
determining the host range of viruses. Both viral
nucleic acids and viral proteins seem to be targeted by
host factors conferring anti-viral activities at the early
post-entry steps of viral replication (Freed, 2004;
Stevenson, 2003). For example, the anti-viral activity of
the cellular protein APOBEC3G, which will be described
in more detail below, has recently been demonstrated
to act directly on the viral genome, but is counteracted
by the viral protein viral infectivity factor (Vif) (Sheehy
et al., 2002; Sheehy et al., 2003; Simon et al., 1998).
Another class of factors that direct their action towards
the viral CA protein to inhibit the post-entry pre-inte-
gration events has been termed “restriction factors”
(Besnier et al., 2002; Bieniasz, 2003; Cowan et al., 2002;
Munk et al., 2002; Towers et al., 2000). 
Retroviral restriction factors were originally described
in murine cells that showed controlled susceptibility to
the Friend’s murine leukemia virus (Lilly, 1967). The
gene products controlling resistance of the murine cells
to the virus were identified as Friend virus susceptibility
factors (Fv). One of the Fv genes, Fv1, was particularly
interesting due to its ability to exert restrictive activity
in vitro (Gardner et al., 1980; Hartley et al., 1970; Lilly,
1967; Pincus et al., 1971; Rasheed & Gardner, 1983).
Two alleles of the gene, Fv1b and Fv1n confer resist-
ance to the B-tropic and N-tropic murine leukemia
viruses, respectively (Hartley et al., 1970; Pincus et al.,
1971). Intriguingly, the Fv1 protein itself seems to have
a retroviral origin (Best et al., 1996). Its protein
sequence has homology to the capsid-related domain
of the ERV-L family of the endogenous retroviral Gag
proteins. It is not clear how the product of the Fv1 gene
exerts its inhibitory effect on viral replication, although
it is apparent that the restriction occurs post-entry,
after the initiation of reverse transcription but before
the integration (DesGroseillers & Jolicoeur, 1983; Stoye,
1998) (Figure 2A). Since introduction of Fv1 into the
non-murine cells is sufficient to confer resistance to
MLV, it is likely that Fv1 does not require additional
factors unique to the murine cells to exert its function.
In addition, the number of Fv1 protein molecules
within the cell seems to be a limiting factor in
restraining infection. The levels of expression of the
Fv1 protein in the murine cells are very low, and it has
been demonstrated that even though the FV1-medi-
ated restriction is relatively strong, it can be abrogated
by saturation of the target cells with non-infectious
virus particles derived from the susceptible cells (Boone
et al., 1990). These observations, combined with the
finding that the determinant of the virus to the Fv1
resistance maps to a single amino acid at position 110
of the capsid protein, suggest a model where restric-
tion is mediated by direct association of the Fv1 protein
with the incoming capsid (DesGroseillers & Jolicoeur,
1983; Goff, 1996; Kozak & Chakraborti, 1996). This
model, although attractive, remains to be proven.
In recent years it became clear that the inhibitory
activity of restriction factors is not limited to murine
cells, but rather is widespread throughout the
mammalian family (Towers et al., 2000). Restriction
factors are now considered one of the major driving
forces of species-specific infection by retroviruses
(Bieniasz, 2003). In human cells, which do not express
Fv1, but are still resistant to infection with N-MLV, a
factor termed restriction factor 1 (Ref1) exerts
inhibitory activity on the viral spread in a manner
highly reminiscent of Fv1 restriction in murine cells
(Towers et al., 2002) (Figure 2B). While the restrictive
activity of Ref1 appears to take place at the early post-
entry stages of viral infection, at or before the initia-
tion of reverse transcription, the Fv1 factor appears to
mediate its effect after the initiation of the reverse
transcription (Figure 2). Remarkably, the viral determi-
nant that controls restrictive ability of Ref1 maps to the
same amino acid within the capsid sequence as that of
Fv1, suggesting a strong evolutionary connection
between the two factors (Towers et al., 2000). 
In primate cells, a similar mode of restriction is medi-
ated by a group of factors collectively termed lentivirus
susceptibility factor 1 (Lv1) (Hatziioannou et al., 2003;
Towers et al., 2000) (Figure 2B). The presence of Lv1
factors in cells of Old World and New World monkeys
confers resistance to infection by HIV-1, and similar to
the cases of Fv1 and Ref1, restriction is determined by
the viral capsid (Towers et al., 2000). Unlike Fv1, which
has been shown to specifically restrict MLV, but not the
lentiviruses, Lv1 and Ref1 seem to restrict infection by
numerous divergent retroviruses (Bieniasz, 2003;
Hofmann et al., 1999; Towers et al., 2000) (Figure 3). In
the case of Lv1, a particularly interesting example of
such diversified restriction is represented by primate
cells derived from African Green Moneys (AGM) that
are resistant to infection by HIV-1, HIV-2, N-MLV,
SIVmac, and Equine infectious anemia virus (EIAV). In
!SCIENTIFIC REVIEW
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FIGURE 3: Species-specific Restriction to Retroviruses.
A. Fv1-mediated Restriction: Different alleles of Fv1 expressed in mouse cells restrict infection by distinct
strains of murine leukemia virus (MLV). While mouse cells homozygous for the “n” allele (Fv1n/n) are effi-
ciently infected by N-tropic MLV strains (N-MLV), cells from mice homozygous for the “b” allele (Fv1b/b)
are efficiently infected by B-tropic strains (B-MLV). Neither N- nor B-MLV viruses efficiently infect heterozy-
gotes since Fv1 is co-dominant. Neither of the alleles Fv1n or Fv1b restrict infection by a third class of MLV
strains (NB-tropic). Mice that carry a null allele, Fv1°, are susceptible to infection by N-, B- and NB-tropic
MLV strains.
B. Lv1/Ref1 mediated restriction. Species-specific variants of TRIM5α (also known as Lv1 or Ref1) impose
highly variable restriction on the replication of divergent retroviruses in primate and human cells. The
restricted viruses are represented in red and the unrestricted viral strains are depicted in green. Abbrevi-
ations: EIAV, equine infectious anemia virus; HIV-1, human immunodeficiency virus type 1; HIV-2, human
immunodeficiency virus type 2; MLV, murine leukemia virus; SIV, simian immunodeficiency virus.
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human cells, restriction by Ref1 also efficiently inhibits
N-MLV and EIAV (Besnier et al., 2002; Cowan et al.,
2002; Hatziioannou et al., 2003). Heterokaryon studies
have demonstrated that these factors act in a dominant
way to restrict infection (Cowan et al., 2002; Munk et
al., 2002). In addition, despite the wide divergence of
the retroviruses that are restricted in primate and
human cells, a series of abrogation studies have
demonstrated that the same restriction factor is domi-
nantly mediating the restriction of various incoming
viruses within the cell (Besnier et al., 2002; Cowan et
al., 2002; Hatziioannou et al., 2003). These studies have
elegantly shown that when the cells are saturated with
virus-like particles derived from one type of retrovirus
that is restricted in these cells, and then infected with
another type of virus, restriction is abrogated. Satura-
tion of the cells with non-restrictive virus particles does
not diminish the restriction, supporting the idea of
specific recognition of the viral capsid molecules by a
single type of factor in these cells. This notion of a
single factor that selectively recognizes a variety of
capsids is quite remarkable. It also strongly suggests
that the restriction factors present in mammalian cells
are evolutionarily closely related to each other. A series
of recent reports confirmed this notion when it was
revealed that Ref1 and Lv1 belong to a single family of
tripartite interaction motif 5α (TRIM5α)-containing
proteins (Hatziioannou et al., 2004; Keckesova et al.,
2004; Perron et al., 2004; Yap et al., 2004).
TRIM5α-α: Unified Host Restriction Factor?
A breakthrough study that has allowed recognition of
these factors identified the cytoplasmic body compo-
nent TRIM5α as an HIV-1 restriction factor in rhesus
monkey cells (Stremlau et al., 2004). The rhesus monkey
TRIM5α protein has been shown to confer resistance to
HIV-1 much more potently than human TRIM5α, and
the determinant of the restriction by TRIM5αrh has
been mapped to the HIV-1 capsid. The mode of action
by TRIM5αrh to confer restriction, as well as the speci-
ficity of its effects have been recognized as highly
similar to that of Lv1 factors, and, in a short time, have
led to the identification of species-specific variants of
the TRIM5α proteins that have bona fide Ref1- and Lv1-
type restriction activity. The human TRIM5α protein has
been definitively shown to account for Ref1 activity in
human cells. When TRIM5αh is expressed in permissive
cells, the cells become resistant to infection by N-MLV,
but not B-MLV. At the same time, when the expression
of the TRIM5αh is abrogated in human cells, the cells
are sensitized to infection by N-MLV. Species-specific
variants of primate TRIM5α protein have also been
identified and have been demonstrated to confer
restriction to an array of retroviruses in the manner of
Lv1. AGM TRIM5α has been shown to protect cells from
infection by HIV-1 and SIVmac, as well as the nonpri-
mate lentivirus EIAV, and at the same time allowing
replication of AGM SIV. Consistent with its function as
the Lv1 restriction factor, siRNA-induced abrogation of
AGM TRIM5a made the AGM cells susceptible to infec-
tion by HIV-1. Several studies have thus concluded that
the species-specific isoforms of the single polymorphic
factor TRIM5α perform the function of Lv1 in Old
World monkeys. 
The fact that variations of the single factor are able to
specifically confer restriction through recognition of
the viral capsid is unprecedented (Owens et al., 2004;
Owens et al., 2003). The capsid proteins of retroviruses,
although conserved, vary significantly from one virus
to another. At the same time, N-MLV and B-MLV capsids
differ by only a few amino acids, and this difference is
sufficient to confer resistance. Specific conformational
changes of capsid proteins are therefore likely to
contribute to the specificity of recognition by the
restriction factors. It is also possible that the ability of
capsids to interact with other species-specific host
factors contributes to the specificity of the restriction.
In one case of the New World primates, this notion has
been recently confirmed. Among the New World
primates, the owl monkey is the only species that is
restrictive to infection by HIV-1 (Hofmann et al., 1999).
Interestingly, restriction by Lv1 in these primates
requires interaction of the viral CA with the cellular
factor Cyclophilin A (CypA) (Towers et al., 2003).
Studies have demonstrated that the disruption of the
interaction between the HIV-1 capsid and CypA by
means of mutating the interaction domain of CA, or
using drugs that abrogate the interaction by seques-
tering CypA, relieved restriction to the HIV-1 infection
in these cells. The fact that the CA-CypA interaction is
required for sustained restriction in the owl monkey
cells is paradoxical since, in human cells, the same type
of interaction seems to promote replication of HIV-1
(Braaten et al., 1996; Braaten & Luban, 2001). An inter-
esting discovery has recently been made that might
explain the connection between the TRIM5α-mediated
restriction in these cells and CypA. An overview of this
discovery, as well as its implications will be discussed
below in the description of CypA.
Cyclophilin A
Cyclophilins are a part of a large family of cellular factors
that were originally shown to interact with the allo-
graft rejection immunosuppressive drug cyclosporine
(Thali, 1995; Wiederrecht et al., 1993). One of the
members of this family of about 15 proteins, CyPA, has
been shown to directly interact with the N-terminal
domain of CA (Luban et al., 1993). The interaction of
CyPA with the proline-rich loop in the CA domain of
GAG allows incorporation of CyPA into HIV-1 particles
in a stoichiometric ratio of CA to CyPA of roughly 10:1
(Franke et al., 1994; Thali et al., 1994). Although the
mechanism of CyPA action in the viral lifecycle remains
elusive, it appears to be important for efficient HIV-1
replication (Braaten et al., 1996; Braaten & Luban,
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2001; Franke & Luban, 1995; Saphire et al., 2000). The
cellular function of CyPA as a cis-trans prolyl isomerase
had been originally speculated to play a role in viral
assembly, but later studies have shown that blocking
CyPA incorporation does not affect virus particle
assembly and release. At the same time it has been
demonstrated that CyPA is required for normal HIV-1
replication kinetics, and abrogation of CyPA expression
by specific knockdown results in reduced infectivity of
HIV-1 particles (Braaten & Luban, 2001). Disruption of
the interaction between the CypA and CA pharmaco-
logically with Cyclosporin A, which binds competitively
to the CA-interacting sites of CyPA, or by mutagenesis
of the CyPA-binding residues of CA, results in abroga-
tion of CyPA encapsidation into virions. Such virions are
able to undergo normal assembly and release, but their
infectivity is reduced for the next round of infection.
The virions depleted of CyPA are blocked at early
stages of reverse transcription, suggesting the require-
ment of CyPA for the early post-entry steps of replica-
tion (Towers et al., 2003). 
Connecting Restriction to CypA
A link between restriction and CyPA was revealed when
it was shown that HIV-1 virions, harboring CA mutants
defective for CyPA binding, were poorly infectious in
human cells expressing Ref1 (Towers et al., 2003).
Surprisingly, the restriction was eliminated by pre-
treating cells with virus-like particles containing the
CyPA-binding CA mutant, suggesting that Ref1 was
saturated with the mutant CA. This observation clearly
established the connection between restriction and
CyPA (Towers et al., 2003). Moreover, the region of CA
that confers the sensitivity to the post-entry block was
mapped near the CyPA-binding loop (Kootstra et al.,
2003; Owens et al., 2004). The above results, combined
with several other observations, led to a current model
which proposes that the interaction between the CyPA
and CA in human cells protects HIV-1 Gag from Ref1-
mediated restriction (Towers et al., 2003). The paradox
observed in owl monkey cells does not fit into such a
model since, in these primate cells which are restricted
to HIV-1 infection, disruption of the CA-CyPA interac-
tion alleviates restriction. This suggests that, unlike in
human cells, CyPA is required for Lv-1-mediated activity
(Towers et al., 2003).
One recent study has demonstrated that abrogation of
CyPA expression by RNAi knockdown in owl monkey
kidney (OMK) cells relieved the restriction to HIV-1
infection, and confirmed the requirement of CyPA to
mediate restriction by Lv1 (now referred to as TRIM5α)
(Sayah et al., 2004). Surprisingly, re-introduction of
CyPA back into the OMK cells did not restore restriction
to HIV-1 infection. An unexpected explanation of this
phenomenon was found when it was realized that a
previously unidentified mRNA, homologous to CyPA,
was targeted by siRNA in the above experiments. The
protein encoded by this mRNA turned out to contain
the sequences of both TRIM5α and CyPA. The presence
of this novel chimeric protein that contains 299 N-
terminal amino acids of TRIM5α, linked to the complete
CyPA sequence at the C-terminus, appears to be essen-
tial for mediating the restriction in the owl monkeys, as
reconstitution of TRIM5α-CyPA in the cells knocked
down for CyPA restores restriction to HIV-1. Since other
New World monkeys lack the restriction to HIV-1, the
TRIM5α-CyPA protein is likely to be unique to the owl
monkey species (Sayah et al., 2004). Discovery of this
novel protein is likely to be followed in the near future
by the multitude of other species-specific factors medi-
ating restriction. The demonstration of the highly
specific restrictive action by these newly found but
uncharacterized proteins marks the beginning of the
unraveling of the highly complex system of antiviral
defense built by mammalian cells throughout evolu-
tion. Elucidating the mechanism of the restrictive
factors’ actions and understanding the evolutionary
processes that stand behind formation of these factors
are clearly of critical importance in both understanding
the roots of retroviral epidemics and the design of anti-
viral therapeutic strategies. 
APOBEC3G
In addition to the activities of the restriction factors
that target the CA of the incoming virus, an activity
against the viral nucleic acids has been shown to
contribute to early post-entry antiviral cell defense 
(Sheehy et al., 2002). Recent studies have demonstrated
that this anti-viral activity, at least in part, is attributed
to the cellular factor APOBEC3G (Apolipoprotein B
mRNA-editing enzyme, catalytic polypeptide-like 3G;
also known as CEM15) (Harris et al., 2003; Lecossier et
al., 2003; Mangeat et al., 2003; Mariani et al., 2003;
Sheehy et al., 2003; Stopak et al., 2003; Zhang et al.,
2003). This protein, expressed in human T lymphocytes,
exerts its function through the interaction with one of
the viral auxiliary proteins, Vif. Vif has long been recog-
nized as a factor that enhances the infectivity of HIV-1,
but, until recently, its mode of action was not clear.
Interestingly, despite the fact that Vif acts during early
stages of viral replication, its presence is required in the
producer cells rather than in the target cells. The obser-
vation that infectivity of Vif-defective virions is pre-
determined exclusively by the type of cells used to
produce the virus, suggested that the producer cells
contain activity that is somehow counteracted by Vif.
APOBEC3G has been shown to account for such an
activity, and its presence in the producer cells renders
Vif-negative virions non-infectious. Several studies
have demonstrated that when Vif is present in the
producer cells, it binds to APOBEC3G and promotes its
degradation. In the absence of Vif, APOBEC3G is incor-
porated into the virus particles, and upon the entry of
the APOBEC3G-carrying virus into the newly infected
cell, it exerts its intrinsic cytidine deaminase activity on
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the minus strand DNA product of viral reverse tran-
scription. Conversion of cytosines to uracils catalyzed
by APOBEC3G on the minus strand viral DNA triggers
the response by the host uracil-DNA glycosidases and
repair enzymes, leading to degradation of the viral
DNA, and thus to limiting the quantity of the viral
cDNA available for subsequent replication steps. The
cDNA that escapes the degradation undergoes G-to-A
hypermutation, which accounts for limitation in the
quality of the viral cDNA that is produced. As a result,
the virus is severely impaired in its ability to proceed to
steps following reverse transcription.
Reverse Transcription and Uncoating 
Assuming that the virus successfully evades the
antiviral responses mounted by the cell upon entry, the
viral nucleoprotein complex is released into the cyto-
plasm and proceeds to reverse transcribe the viral RNA
genome. The process of reverse transcription is
catalyzed by the virally encoded enzyme reverse tran-
scriptase (RT). The DNA polymerase activity of RT that is
capable of using both DNA and RNA as templates
converts the viral RNA genome into the double-
stranded DNA molecule (Telesnitsky and Goff, 1997).
Although the mechanistic details of reverse transcrip-
tion are fairly well understood, the timeline of the
process with respect to the uncoating, as well as the
extent of the involvement of the cellular environment
are not very clear and undergoes continuous reassess-
ment (Goff, 2001a; Goff, 2001b). The initial hypothesis,
originating from the studies of the yeast Ty retrotrans-
position elements, suggested that reverse transcription
takes place in the shell-like enclosed environment
containing RT, IN and CA proteins, and is permeable to
dNTPs (Bowerman et al., 1989; Brown et al., 1987;
Brown et al., 1989; Eichinger & Boeke, 1988; Garfinkel
et al., 1985). The notion of reverse transcription taking
place within a sequestered viral core, protected from
the cellular environment, was supported by the
discovery of the MLV capsid protein within preintegra-
tion complexes (Bowerman et al., 1989; Fassati & Goff,
2001). However, subsequent studies demonstrated that
early post-entry steps of HIV-1 differed from that of
MLV, as the reverse transcription complexes (RTC)
isolated from HIV-1-infected cells contained only trace
amounts of CA (Fassati & Goff, 2001; Karageorgos et
al., 1993; Miller et al., 1997). A series of elegant studies
demonstrated that the in vitro reverse transcription of
purified HIV-1 virions was greatly enhanced in the pres-
ence of physiological fluids (Zhang et al., 2000; Zhang
et al., 1996; Zhang et al., 1998). In this so called
endogenous reverse transcription assay, the virions
were shown to undergo profound morphologic
changes of the viral core in the absence of detergents.
Together, the above results suggested that reverse
transcription is likely to coincide with the process of
uncoating and to involve cellular proteins (Nermut &
Fassati, 2003). Results of the recently published EM
studies of HIV-1 reverse transcription complexes
support this hypothesis (McDonald et al., 2002; Nermut
& Fassati, 2003). These studies revealed that the RTCs
were large nucleoprotein complexes containing
numerous proteins, and that they resembled fibers of
histone H1-depleted chromatin.
It is clear that the involvement of cellular factors in
reverse transcription is just beginning to be unraveled.
Since reverse transcription and uncoating seem to coin-
cide in time within the same cellular compartment, it is
possible that host factors involved in the uncoating may
also contribute to reverse transcription and vice versa.
It is also possible that reverse transcription is function-
ally linked to other steps of replication through
common use of cellular factors.
Formation and Nuclear Translocation 
of Pre-Integration Complexes
The process that follows reverse transcription involves
assembly of the newly synthesized cDNA molecules into
preintegration complexes (PICs). HIV-1 PICs have been
characterized as large nucleoprotein complexes that, in
addition to the viral nucleic acids, contain IN, RT, Vpr,
MA and several known and unknown cellular compo-
nents (Fouchier & Malim, 1999; Sherman & Greene,
2002). The host cell factors that have been shown to be
part of PICs include HMG(I)Y, BAF, and LEDGF. 
The ability of HIV-1 PICs to actively penetrate the
nuclear membrane to gain access to the nucleus of the
cell defines the uniqueness of HIV-1 and other
lentiviruses, since they can infect non-dividing cells
(Lewis & Emerman, 1994). Unlike lentiviruses, oncoretro-
viruses require disintegration of the nucleus during
mitosis to gain access to the host genome. Lentiviruses
have developed a means of actively transporting PICs
through the nuclear membrane and, although the
mechanism of such transport remains elusive and highly
controversial, it is clear that it relies heavily on the
cellular machinery. The simple fact that the size of the
PIC is over twice the size of the nuclear pore complex
(NPC) channel argues against the passive passage of the
PIC into the nucleus. Indeed, studies have demonstrated
that the nuclear translocation of PICs involves an active
ATP-dependent mechanism (Bukrinsky et al., 1992).
Several viral proteins have been identified to potentially
mediate nuclear import of PICs. IN, MA and Vpr all
contain nuclear localization sequences that have been
implicated in the nuclear localization of PICs (Bukrinsky
& Haffar, 1999; Bukrinsky et al., 1993). The question of
requirement of the nuclear localization signal of these
factors in this process remains highly debated and
controversial (Bouyac-Bertoia et al., 2001; Dvorin et al.,
2002; Fouchier et al., 1997; Gallay et al., 1997; Sherman
& Greene, 2002).
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The functional components of the NPC such as
importins probably play an active role in the transloca-
tion of the PICs into the nucleus of the target cell
(Gallay et al., 1997; Gallay et al., 1996). Importins are
known to specifically recognize the nuclear localization
signal of cytoplasmic proteins and can mediate their
transport through the NPC by utilizing the gradient of
RanGTP to RanGDP that forms across the nuclear
membrane. It remains to be determined whether this
classical import mechanism is utilized by HIV-1 PICs.
HOST FACTORS IN LATE EVENTS
Viral Transcription
Transcription of the integrated HIV-1 provirus is a
crucial step in the viral lifecycle that involves a highly
regulated interplay between the virus and the host
apparatus (Kingsman & Kingsman, 1996; Pereira et al.,
2000). Various cell type-specific transcriptional activa-
tors as well as suppressors of transcriptional inhibitors
are utilized to induce maximal viral transcription. Such
an ability by the virus to adapt to the cell-specific envi-
ronment allows for the rapid viral replication in a
variety of cells, and at the same time ensures mainte-
nance of latently-infected reservoirs that are activated
for transcription only when the need arises. 
The major viral regulator of proviral transcription is the
Tat protein, which potently enhances gene expression
by binding directly to the TAR region of the HIV-1
promoter, the long terminal repeat (LTR) (Gatignol et
al., 1996; Gatignol & Jeang, 2000; Gaynor, 1995). The
ability of Tat to activate transcription is driven by its
association with a number of cellular transcription
factors. One crucial cellular protein required for Tat
transactivation activity has been identified as CyclinT1,
which directly associates with Tat. This association, in
turn, recruits a cyclin-dependent kinase (CDK9) to the
TAR sequence, and leads to the formation of transcrip-
tion elongation complex, known as positive transcrip-
tion elongation factor b (P-TEF-b) (Garber et al., 1998;
Wei et al., 1998). Formation of this complex results in
subsequent hyper-phosphorylation of the C-terminus
of RNA polymerase II, and leads to the efficient elon-
gation of nascent RNA molecules.
In addition to Cyclin T1, Tat directly interacts with the
cellular transcription factor Sp1 (Kamine & Chin-
nadurai, 1992; Kamine et al., 1991). Interaction
between the Tat and Sp1 proteins seems to be required
for the transactivation ability of Tat in all types of cells.
Moreover, Sp1 itself exerts both cell-specific, and
differential state-specific transcriptional activity on the
proviral transcription, as it acts as an antagonist to
another Sp-family factor, Sp3, which is known to
repress LTR-driven transcription in certain cells. Inter-
estingly, Sp1 also bypasses the requirement for Tat/Tar
to drive proviral transcription by the direct recruitment
of Cyclin T1 to the LTR (Yedavalli et al., 2003). A similar
activity has been ascribed to another key cellular factor
demonstrated to transactivate the LTR, nuclear factor
κB (NF-κB). The NF-κB transcription factor is involved in
multi-level regulation of proviral transactivation.
During HIV-1 infection, a cell-specific activation of the
NF-κB pathway by the virus leads to the liberation of its
two subunits, p50 and p65, from the cytoplasmic
inhibitor IκB, and the translocation of NF-κB to the
nucleus, where it binds to the specific target sequences
of the LTR and stimulates transcription (Rabson & Lin,
2000). Induction of LTR transcription by NF-κB has been
linked to acetylation of NF-κB by the cellular coacti-
vator p300 (Furia et al., 2002). Coactivator proteins
such as CBP/p300 and pCAF are thought to mediate the
Tat-induced transcriptional activation of the LTR
promoter through the remodeling of HIV-1 containing
chromatin structure. These factors also seem to
mediate acetylation of the Tat itself and thus promote
its activity.
Among the growing list of other cellular factors
contributing to the establishment of equilibrium in the
transcription of the proviral genome are such tran-
scription factors as nuclear factor of activated T-cells
(NFAT), which bind to an enhancer element in the LTR
in T cells (Cron et al., 2000). The differential effect by
two types of NFAT proteins, NFAT-1 and NFAT-2/NFAT-c
allows either synergistic action with NF-κB and Tat to
stimulate transactivation in cells such as activated T
lymphocytes or inhibition of the NF-κB-mediated trans-
activation in resting lymphocytes (Mouzaki et al.,
2000). 
Inhibition of LTR transactivation involves a number of
cellular factors and can be viewed as both a way for the
cell to mount an anti-viral response and as a potent
mechanism to establish latency. Several key transcrip-
tion factors that have been identified to counteract
Tat-mediated transactivation include tumor suppressor
p53, which has been shown to associate with Tat, tran-
scription factor Ying Yang1 (YY1) and lysofylline (LSF)
(Coull et al., 2000; Duan et al., 1994; Li et al., 1995). The
latter two cellular factors inhibit HIV-1 expression by
the recruitment of the histone deacetylase activity to
the LTR, which counteracts TAT-driven LTR transactiva-
tion (Coull et al., 2000). 
Assembly and Budding 
Upon successful export of viral RNA molecules into the
cytoplasm, viral proteins are synthesized from the
mRNAs in the form of large polyprotein precursor mole-
cules. These polyprotein precursors are then assembled
into the nascent viral particles, along with the viral
genomic RNA and cellular proteins, (Gottlinger, 2001;
Kaplan, 2002). Although it is clear that the assembly
involves cellular factors, the identities of many of these
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factors, as well as the extent of their involvement,
remain widely unknown. The major viral determinant in
the assembly is considered to be Gag polyprotein, since
the expression of the retroviral Gag protein itself is
sufficient for the formation and release of virion-like
particles (VLPs) (Gheysen et al., 1989). The process of
assembly is arbitrarily divided into the following steps,
some of which are likely to occur concurrently: 1) multi-
merization of Gag molecules; 2) binding of Gag
complexes to viral genomic RNA; 3) formation of Gag-
Gag/Pol complexes mediated by Gag; 4) formation of
high order complexes containing viral proteins and host
cell proteins required for assembly and budding; 5)
cytoskeleton-directed transport of preassembled
complexes to the inner plasma membrane of the cells.
Cellular factors that influence viral assembly include
HP68 and Tumor Susceptibility gene 101 (Tsg101). HP68,
an RNAse L inhibitor that was purified from the in vitro
reconstituted assembly system, is suggested to promote
the assembly of Gag into immature virus particles. It
associates with Gag, Gag-Pol and Vif, and is selectively
incorporated into the preassembled viral complexes
(Zimmerman et al., 2002).
TSG101 protein, coupled with other cellular factors of
the endosomal sorting machinery, such as Vsp28 and
Vsp4, has been shown to bind to the PTAP motif of the
Gag p6 to promote budding of the virus particle.
Studies preceding identification of TSG101 demon-
strated that the L domain of Gag that contains the
conserved PTAP motif was responsible for the efficient
budding of the nascent virions from the host cell.
Mutations in this region caused blockage of the virions
at the stage of budding and caused accumulation of
Gag into VLPs that do not detach from the plasma
membrane (Dorfman et al., 1994; Gheysen et al., 1989;
Huang et al., 1995). The L domain was shown to facili-
tate a late budding process at the stage of membrane
fusion required for the release of the assembled parti-
cles. Several studies, such as functional swapping of the
L domains of various retroviruses, and placement of the
p6 region into various locations within Gag suggested
that the mode of action by which the L domain
promotes budding is through its protein-protein inter-
actions with cellular factors. The L domain was further
shown to associate with the cellular ubiquitination and
endosomal sorting machinery, and one factor from this
pathway, TSG101, was identified to directly bind to p6
(Garrus et al., 2001; VerPlank et al., 2001). The cellular
functions of TSG101 and associated Vsp proteins in the
endosomal sorting pathway have been proposed to be
utilized by the virus to promote budding. The mecha-
nism by which HIV-1 employs the cellular endosomal
sorting machinery, and specifically TSG101, has not
been completely elucidated. The current favored
hypothesis is that the L domains recruit the cellular
endocytosis machinery to the site of budding to
promote the specific sorting of the ubiquitinated cargo
into the forming viral particles. Tsg101 has structural
and sequence similarity to the ubiquitin-conjugating
enzymes, and the efficient release of virus particles
requires the ability of TSG101 to bind both PTAP and
ubiquitin (Goff et al., 2003). Furthermore, the affinity
of Tsg101 for Gag is enhanced when Gag is ubiquiti-
nated (Garrus et al., 2001; Martin-Serrano et al., 2001;
Pornillos et al., 2002). Results of the mutational
analyses of Tsg101 are also in support of the above
hypothesis, as Tsg101 truncation mutants inhibit
budding of the virus by binding to the L domain and/or
by disrupting the endosomal sorting pathway of the
host cell (Goila-Gaur et al., 2003).
INI1/hSNF5
Late events of HIV-1 replication also seem to involve
another cellular factor, INI1/hSNF5, which was originally
identified as a host protein that specifically binds to HIV-
1 IN (Kalpana et al., 1994). INI1 is homologous to yeast
SNF5 and is a component of the chromatin remodeling
hSWI/SNF complex (Kalpana et al., 1994; Wang et al.,
1996). SWI/SNF and related complexes are evolutionarily
conserved, multi-subunit, high molecular weight
(>2MDa), ATP-dependent complexes that regulate tran-
scription by chromatin remodeling in eukaryotic cells
(Carlson & Laurent, 1994; Peterson, 1998; Peterson &
Tamkun, 1995; Wolffe, 2001). The function of INI1/hSNF5
within the context of SWI/SNF complex and its exact role
in chromatin remodeling is presently unknown.
Creating a transdominant mutant can genetically test
the role for a host protein in viral replication. A study
has demonstrated that a truncation mutant of INI1
(termed S6) that harbors the minimal IN-interaction
domain had a dramatic effect on the HIV-1 particle
production, exhibiting up to 100,000-fold inhibition in
293T cells (Yung et al., 2001). Furthermore, it was
found that expression of this mutant in T-cells
protected these cells from the spread of the virus.
These studies indicate that the inhibition is mediated
by the direct protein-protein interaction between S6
and IN. Furthermore, it was found that HIV-1 particle
production is reduced in INI1-deficient cells and that
INI1/hSNF5 complements the defect (Yung et al., 2001).
The above results suggested that INI1/hSNF is involved
in the late stages of the viral lifecycle, although its
precise role, as well as the mechanism of its action
remains unclear. In addition, during the course of
above studies, it was found that INI1/hSNF5 is incorpo-
rated into HIV-1 virions. Furthermore, incorporation of
INI1/hSNF5 was specific to HIV-1 and was dependent on
its ability to specifically interact with HIV-1 IN, indi-
cating that HIV-1 may have evolved to utilize this host
factor during its replication (Yung et al., 2004). 
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CONCLUSION
Until recently, the responses of the humoral and
cellular immune systems were considered to be the
major driving forces of mammalian host defence
against viral pathogens including HIV-1. However,
recent studies on the intracellular host-virus interac-
tions illustrate the fact that host restriction factors
strongly oppose HIV-1 replication within the cell and
implicate the intricate dynamics in the battle between
the host and HIV-1. These studies also illustrate the
ingenuity of HIV-1 in its ability to hijack host cellular
factors to assist in its propagation. It is clear that we do
not yet fully understand all the players and the mecha-
nisms involving host cell defence systems, and it is likely
that there are many more host factors that mediate the
intracellular immunity against infection by HIV-1.
Further studies to elucidate the mechanism of intracel-
lular host defence will not only provide new insights
into this ancient battle between the host and the virus,
but may also lead to the development of novel strate-
gies to combat the onslaught by the virus. These novel
strategies could include an array of interventions that
could either mimic the natural defence mechanisms of
the host or disrupt the adaptive mechanism of the
virus, providing us with a powerful arsenal for the war
against the currently devastating AIDS pandemic.
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